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Background: Systemic capillary leak syndrome is a rare disease with a high mortality rate. This syndrome is
characterised by generalised edema, hypotension, hemoconcentration, and hypoproteinemia. The cause is the
sudden onset of capillary hyperpermeability with extravasations of plasma from the intravascular to the
extravascular compartment. We present the case of a patient who experienced two episodes of systemic capillary
leak syndrome and pulmonary hypertension; the first after gemcitabine in an adjuvant setting and the second three
years later after treatment with nab-paclitaxel for metastatic disease.
Case presentation: A 65-year-old patient underwent a pancreatectomy in January 2010 for ductal carcinoma
(pT3 N0 M0, stage IIa), followed by adjuvant chemotherapy. Seven days after the last cycle, she developed dyspnea
associated with orthopnea and cough. A transthoracic cardiac ecocolordoppler was performed, with evidence of
pulmonary hypertension (58 mmHg). Blood tests showed an increase in creatinine, pro-BNP and D-Dimer. She
began high-dose diuretic therapy combined with cortisone. After a month, the patient was eupneic and the
anasarca had resolved. We decided gradually to reduce the steroid and diuretic therapy. After ten days of the
reduction, the patient began to re-present the same symptoms after treatment with gemcitabine. Corticosteroid
therapy was restored with rapid clinical benefit and decreased pro-BNP after a week of treatment. After two years,
the disease returned. As a first line treatment, it was decided to use nab-paclitaxel 100 mg/m2 weekly. After two doses,
followed by approximately 14 days of treatment, the patient developed acute respiratory distress syndrome. The clinical
suspicion was a relapse of capillary leak syndrome and treatment with a high-dose diuretic (furosemide 250 mg daily)
was started combined with cortisone (40 mg methylprednisolone). The patient showed a progressive clinical benefit.
Conclusions: In patients treated with gemcitabine and nab-paclitaxel who experience a sudden onset of diffuse
edema with respiratory distress, capillary leak syndrome should be suspected. Immediate treatment with corticosteroids
may be life-saving.
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Gemcitabine is an antimetabolite pyrimidine, active mainly
on tumours of the pancreas, lung (excluding small cell),
ovary, breast and bladder [1,2]. Gemcitabine is generally
well-tolerated by patients. It can cause pulmonary toxicity
in rare cases [3]. The literature also reports cases of throm-
botic microangiopathy related to treatment with gemcita-
bine [4], along with capillary leak syndrome. Nab-paclitaxel
was well-tolerated. Non-hematological toxicities were gen-
erally mild with grade 1–2 nausea, anorexia, hypocalcemia
and vomiting. Grades 3–4 of neutropenia, neutropenic
fever, and anemia occurred in 32%, 1% and 11% of pa-
tients, respectively [5]. There are no cases of capillary leak
syndrome documented in the literature from the use of
this drug.
Case presentation
A 65-year-old patient underwent a pancreatectomy in
January 2010 for ductal carcinoma (pT3 N0 M0, stage IIa).
Medical history: in 1994, she underwent an operation
for ovarian cancer and was treated with cisplatin, cyclo-
phosphamide and doxorubicin. The treatment was well-
tolerated, with no specific toxicity. For the pancreatic
cancer, she received adjuvant chemotherapy with gemcita-
bine (1000 mg/m2 days 1,8,15 every 28 days) from March
2010 to September 2010. During the adjuvant treatment
the patient took insulin, aldactone 100 mg, dilatrend and
cardioaspirin. Chemotherapy was well-tolerated. Seven days
after the last cycle, she developed dyspnea associated withFigure 1 Transthoracic cardiac ecocolordoppler showing evidence of
hypertension and ejection fraction (C-D).orthopnea and cough. An objective examination showed
initial anasarca. A transthoracic cardiac ecocolordoppler
was performed with evidence of pulmonary hypertension
(58 mmHg) (Figure 1A). The ventricular ejection fraction
was normal (68%) (Figure 1B). Blood tests during treat-
ment with chemotherapy were always normal; she now
showed an increase in creatinine (1.96 mg/dl), pro-BNP
(6425 pg/ml), D-Dimer (636 ug/L) and LDH (503 U/L).
There was a decrease in total protein (56 g/l) while, one
month previously, total protein had been normal. A CT
scan showed bilateral pleural effusions, ascites and the
appearance of slight thickening of interlobular septa pre-
dominantly at the apices and bases, suggestive of edema-
tous imbibition (Figure 2A-B). Capillary leak syndrome was
suspected and the patient was started on high-dose diuretic
therapy (furosemide 250 mg daily) combined with cortisone
(40 mg methylprednisolone). A slow but progressive clinical
benefit was seen. After one month, the patient was eupneic
and the anasarca had resolved. A transthoracic cardiac
ecocolordoppler was performed with evidence of persistent
pulmonary hypertension (44 mmHg). Blood tests showed a
persistent rise in creatinine (1.61 mg/dl) with decreased
pro-BNP (973 pg/ml). We decided gradually to reduce the
steroid (methylprednisolone up to 5 mg per day) and diur-
etic (furosemide 25 mg per day) therapy. After ten days of
the reduction, the patient began to re-present the same
symptoms after treatment with gemcitabine. Blood tests
showed an increase in pro-BNP (4896 pg/ml), associated
with a new increase in pulmonary pressure (50 mmHg).pulmonary hypertension (A-B) and normal pulmonary
Figure 2 Chest CT scan showing evidence of pulmonary edema (A, axial plane – B, coronal plane) and disappearance of pleural
effusion and pulmonary edema (C-D).
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benefit and decreased pro-BNP after a week of treatment
(1969 pg/ml).
After three months of treatment with corticosteroids and
diuretics, the pulmonary pressure had returned to normal.
During these three months, the diuretic and steroid therapy
was gradually reduced, until it was finally halted. In
April 2011, the patient was asymptomatic with normal
pulmonary pressure (9.7 mmHg) (Figure 1C).The ven-
tricular ejection fraction was normal (Figure 1D). The
pro-BNP and D-dimer levels had normalised, while
there was still mild renal insufficiency (1.4). A chest
CT scan revealed the disappearance of pleural effusion
and pulmonary oedema (Figure 2C-D).
Three years after the onset of pain in the right hip, a
CT scan of the thorax and abdomen was performed,
with evidence of peritoneal carcinomatosis. As a first-line
treatment, it was decided to start nab-paclitaxel 100 mg/m2
weekly. After two doses, followed by approximately 14 days
of treatment, the patient developed acute respiratorydistress syndrome. A CT scan showed bilateral pleural
effusions, ascites and the appearance of slight thickening of
interlobular septa predominantly at the apices and bases,
likely to be oedematous imbibitions (Figure 3A-B). A
transthoracic cardiac ecocolordoppler was performed
with evidence of pulmonary hypertension (58 mmHg). The
ventricular ejection fraction was normal (79%).
Blood tests during treatment with chemotherapy were
always normal; she now showed an increase in pro-BNP
(4253 pg/ml), D-Dimer (328 ug/L) and LDH (563 U/L).
A relapse of capillary leak syndrome was suspected
and the patient was started with high-dose diuretic ther-
apy (furosemide 250 mg daily) combined with cortisone
(40 mg methylprednisolone). The patient showed a pro-
gressive clinical benefit and, after one week, was eupneic.
A transthoracic cardiac ecocolordoppler was performed
with evidence of the resolution of pulmonary hypertension
(26 mmHg). Blood tests showed a decreased pro-BNP
(324 pg/ml). For the patient, it was decided to resume nab-
paclitaxel with prophylactic cortisone. After two doses, the
Figure 3 Chest CT scan showing evidence of pulmonary edema (A-B).
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asymptomatic. It was decided to discontinue the drug.
Conclusions
Gemcitabine and nab-paclitaxel are generally well-tolerated
but on rare occasions they may have particular toxicity.
This toxicity is documented in the literature [6,7]. It usu-
ally occurs after a certain number of cycles but in some
cases may occur after a single cycle [8,9]. The first case
of gemcitabine and non-cardiogenic pulmonary oedema
is documented by Pavlakis et al. They presented three
cases. Two patients died and the third patient had a
good response from cortisone [8]. Conversely, no case
of capillary leak syndrome has been reported in literature
with nab-paclitaxel.Corticosteroid
decrease
Cortico
incre
Figure 4 Variation in pro-BNP levels and correlation with pulmonaryThe peculiarity of this case is that the patient suffered
two similar episodes of capillary leak syndrome with
two different drugs. The patient saw a benefit with the
administration of cortisone. Furthermore, when we reduced
the cortisone, her symptoms relapsed. The symptoms dis-
appeared after she has taken the initial dose of cortisone.
Capillary leak syndrome is a systemic process charac-
terised by the hyperpermeability of the endothelium
[10]. In this disease there is a rapid extravasation of plasma
from the intravascular compartment to the extravascular
compartment. This is the cause of the symptoms in
patients. The pathophysiology of the damage is not known.
A predictor, although a little sensitive, of capillary leak
syndrome is the decrease of albumin [11]. This syndrome
was described after snake bites [12] in patients with sepsissteroid
ase
Pulmonary 
hypertension
(mmHg)
pro-BNP
(pg/ml)
hypertension.
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taxotere [16]. Endothelial injury caused a loss of produc-
tion of nitric oxide (vasodilator). The lack of production
of nitric oxide probably caused the increase in pulmonary
artery pressure, as caused by vasoconstriction. Pulmonary
hypertension led to an overload of the right ventricle;
from the laboratory point of view, that caused the increase
in pro-BNP.
Our case shows that the variation of pro-BNP is corre-
lated with the clinical patient (Figure 4). During the first re-
mission of symptoms, the pro-BNP decreased to 973. When
the corticosteroid was reduced, there was a resurgence of
the symptoms with an increase of the pro-BNP. A high dose
of cortisone was reintroduced with resolution of the clinical
picture and concomitant progressive reduction of the pro-
BNP. The trend of pro-BNP levels also followed pulmonary
hypertension, suggesting that the lung hypertension was the
cause of the appearance of cardiac dysfunction (Figure 4).
Similarly, during the second episode, the pro-BNP
followed the pulmonary hypertension. As a differential
diagnosis we considered thrombotic microangiopathy, but
the clinical and laboratory tests excluded this hypothesis.
Furthermore, a diagnosis of vasculitis was unlikely as the
indices of inflammation were negative (VES and PCR);
there were also high levels of rheumatoid factor and cryo-
globulins, and hypocomplementemia was not present.
This confirms the direct damage caused by the drug and
the absence of immune-mediated damage.
In conclusion, in patients treated with gemcitabine and
nab-paclitaxel, the sudden onset of diffuse oedema with re-
spiratory distress tends to suggest this syndrome. Immedi-
ate treatment with corticosteroids may save the life of the
patient but it is not effective in preventing the syndrome.Consent
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